DOI: https://doi.org/10.22141/2224-0721.3.59.2014.76663

Pragmatic Pharmacological and Economic Analysis of Insulin Glargin Use in Type 2 Diabetes Mellitus in Ukraine

N.V. Bezdetko, O.N. Kirichenko

Abstract


The article deals with the question of insulin therapy in type 2 diabetic patients. There are demonstrated the results of pragmatic trial of clinical and economic reasonability of transferring of the type 2 diabetic patients from NPH insulin treatment for the therapy with insulin glargin in routine medical practice in Ukraine.


Keywords


diabetes mellitus; insulin; clinical and economic analysis

References


Новости УНИАН 14.11.2013 [Электронный ресурс]. Режим доступа: http: // health.unian.ua/country/851984-v-ukrajini-zrostae-kilkist-hvorih-na-tsukroviy-diabet.html

Health: the high cost of diabetes [Электронный ресурс]. Режим доступа: http: // www.oecd.org/eu/healththehighcostofdiabetes.htm

American Diabetes Association. Economic costs of diabetes in the U.S. in 2007 // Diabetes Care. — 2008. — Vol. 31. — P. 596-615.

American Diabetes Association. Economic costs of diabetes in the U.S. in 2012 // Diabetes Care. — 2013. — Vol. 36. — P. 1033-1046.

Новые технологии в диагностике, профилактике и лечении наиболее распространенных эндокринных заболеваний // Здоровье Украины — 2012. — № 4 (20). — С. 12-13.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) // Lancet. — 1998. — Vol. 352. — Р. 837-853.

Inzucchi S.E. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of ADA and EASD // Diabetologia. — DOI 10.1007/s 00125-012-2534-0

Herman W. The Economic Costs of Diabetes: Is It Time for a New Treatment Paradigm? // Diabetes Care. — 2013. — Vol. 36, № 4. — P. 775-776.

Маньковский Б.Н., Жердева Н.Н. Инсулинотерапия. Что нового? // Международный эндокринологический журнал. — 2013. — № 3 (51).

Vaag A., Lund S.S. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues // Eur. J. Endocrinol. — 2012. — Vol. 166, 32. — P. 159-170.

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes / P. Hollander, J. Cooper, J. Bregnhoj et al. // Clin. Ther. — 2008. — Vol. 30. — P. 1976-1987.

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargin (HOE 901) and NPH insulin / J. Rosenstock, S. Schwarts, C. Clark et al. // Diabetes Care. — 2001. — Vol. 24. — P. 631-636.

Comparison of Insulin Glargine Versus NPH Insulin in People with Type 2 Diabetes Mellitus Under Outpatient-Clinic Conditions for 18 Months Using a Basal-Bolus Regimen with a Rapid-Acting Insulin Analogue as Mealtime Insulin / S. Siegmund, S. Weber, H. Blankenfeld et al. // Exp. Clin. Endocrinol. Diabetes. — 2007. — Vol. 115, № 6. — P. 349-353.

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes / J. Rosenstock, G. Dailey, M. Massi-Benedetti et al. // Diabetes Care. — 2005. — Vol. 28. — Р. 950-955.

Schreiber S.A., Russmann A. The effects of insulin glargine treatment and an educational program on glycaemic control in type 2 diabetes patients in clinical practice // Curr. Med. Res. Opin. — 2006. — Vol. 22, № 2. — Р. 335-341.

The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study / J.S. Fischer, T. McLaughlin, L. Loza et al. // Curr. Med. Res. Opin. — 2004. — Vol. 20, № 11. — Р. 1703-1710.

Use of Antidiabetic Drugs in the U.S., 2003-2012 / C. Hampp, V. Borders-Hemphill, D. Moeny et al. // Diabetes Care. — 2014. — Vol. 37. — P. 1367-1374.

Levin P. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics // Diabetes, Obesity and Metabolism. — 2008. — Vol. 10 (Suppl. 2). — P. 66-75.

Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine / E. Warren, E. Weatherley-Jones, J. Chilcott et al. // Health Technol. Assess. — 2004. — Vol. 8 (45). — P. 1-57.

Наказ МОЗ України від 21.12.2012 № 1118 «Уніфікований клінічний протокол первинної та спеціалізованої медичної допомоги. Цукровий діабет 2-го типу».

Фармакоекономіка / Л.В. Яковлєва, Н.В. Бездітко, О.О. Герасимова та ін. — Вінниця: Нова книга, 2009. — 208 с.

Levin H.M. Cost-Effectiveness Analysis: Methods and Applications. — SAGE Publications, 2001. — 308 p.

Hutton J. Misleading Statistics: The Problems Surrounding Number Needed to Treat and Number Needed to Harm // Pharm. Med. — 2010. — Vol. 24, № 3. — P. 145-149.

Аметов А.С., Белоусов Д.Ю. Фармакоэкономика инсулина гларгин при оптимизации инсулинотерапии сахарного диабета 2-го типа // Качественная клиническая практика. — 2012. — № 2. — С. 13-21.

Аптека on line. — [Электронный ресурс]. — Режим доступа к сайту http: // www.pharmbase.com.ua. — Название с экрана.

Государственный комитет статистики Украины. [Электронный ресурс]. — Режим доступа к сайту http: // www.ukrstat.gov.ua

Белоусов Д.Ю. Фармакоэкономика инсулина гларгина (Лантус) в зеркале зарубежных доказательных исследований: обзор литературы // Клиническая фармакология и терапия. — 2008. — № 17 (2). — С. 84-88.

Grima D.T., Thompson M.F., Sauriol L. Modelling Cost Effectiveness of Insulin Glargine for the Treatment of Type 1 and 2 Diabetes in Canada // Pharmacoeconomics. — 2007. — Vol. 25, № 3. — P. 253-266.

Brandle M., Azoulay M., Greiner R.. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland // International Journal of Clinical Pharmacology and Therapeutics. — 2007. — Vol. 45, № 4. — Р. 203-220.

Evaluation of the costeffectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK / P. McEwan, C. Poole, T. Tetlow et al. // Curr. Med. Res. Opin. — 2007. — Vol. 23, Suppl. 1. — Р. 7-19.

Clissold R., Clissold S. Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value // Core Evidence. — 2007. — Vol. 2. — P. 89-110.






Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2019

 

   Seo анализ сайта